WuXi Biologics (Cayman) company profile
Company profile
WuXi Biologics (Cayman) has 14,705 employees and is headquartered in Wuxi, China.
The company is best known for platforms such as WuXiBody, SDArBodY, WuXiUP and WuXiHigh, which it applies across biologics work. Its activities run from early discovery and the preparation of investigational new drug filings through process development and commercial-scale production, and also include vaccine contract manufacturing, clinical and manufacturing services, and the development, production and distribution of biotechnological products. Operations are organised in two segments, Biologics and XDC, and the company serves customers in China, North America, Europe, Singapore, Japan, South Korea, Australia and Brazil.
In the fiscal year ended December 2025, revenue reached CNY 21.8 billion, up 16.7% from the previous year, and net profit stood at CNY 4.9 billion. The company had 14,705 employees at the end of the period, and it is headquartered in Wuxi, China, where it was incorporated in 2014.
Company facts
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- Hong Kong SAR China
- Headquarters
- No. 108, Meiliang Road, Wuxi
- Employees
- 14,705
- Chief executive
- Zhisheng Chen
- Founded
- 2014
- Fiscal year
- January - December
- Listing
- 2269 · HKEX
- Indices
- Hang Seng
- Currency
- HKD
- ISIN
- KYG970081173
- Website
- wuxibiologics.com
WuXi Biologics (Cayman) and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| WuXi Biologics (Cayman)2269 | Hong Kong SAR China | $24.52B | 14,705 | 32.4% | 35.1 |
| Innovent Biologics1801 | Hong Kong SAR China | $18.84B | 8,754 | 7.4% | 111.5 |
| Celltrion068270 | South Korea | $36.68B | 2,956 | 31.6% | 26.4 |
| Sichuan Kelun-Biotech Biopharmaceutical6990 | Hong Kong SAR China | $13.65B | 2,300 | -0.2% | — |
| Sino Biopharmaceutical1177 | Hong Kong SAR China | $12.49B | 22,838 | 28.2% | 36.7 |
| Samsung Biologics207940 | South Korea | $49.13B | 5,326 | 45.5% | 33.4 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
